Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANURADHA R THUMMALA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1376552745
CMS profile
289760
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$6,747.66

120 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANURADHA R THUMMALA

NPI 1376552745 · CMS profile ID 289760

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1376552745?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANURADHA R THUMMALA, NPI 1376552745, CMS profile ID 289760. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376552745?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ANURADHA R THUMMALA, NPI 1376552745, CMS profile ID 289760. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376552745?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ANURADHA R THUMMALA, NPI 1376552745, CMS profile ID 289760, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–120 of 120 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1376552745?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

120 matching records · $6,747.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 120 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–120 of 120.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $2.1502/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089490798 CMS
Tactile Systems Technology Inc $24.4402/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1082357501 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.5202/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144968938 CMS
Tempus AI, Inc $14.4002/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150175800 CMS
Daiichi Sankyo Inc. $16.5302/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089490796 CMS
Exelixis Inc. $34.6802/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1138555434 CMS
Celgene Corporation $21.1501/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101170520 CMS
Lilly USA, LLC $2.6301/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136000261 CMS
EMD Serono, Inc. $18.0001/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120224577 CMS
Mirati Therapeutics, Inc. $17.5601/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117174469 CMS
Lilly USA, LLC $75.7501/22/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136049315 CMS
Daiichi Sankyo Inc. $16.6901/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089490792 CMS
Daiichi Sankyo Inc. $17.4401/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089490794 CMS
Janssen Biotech, Inc. $16.7401/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078394345 CMS
E.R. Squibb & Sons, L.L.C. $24.0501/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101670482 CMS
PFIZER INC. $26.7401/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131444034 CMS
Novartis Pharmaceuticals Corporation $18.3001/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087421246 CMS
Novartis Pharmaceuticals Corporation $17.6701/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087421244 CMS
Celgene Corporation $17.7001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101170514 CMS
Genmab U.S., Inc. $20.1201/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126824443 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $18,681.70 25
PY2020 $10,717.24 7
PY2021 $9,569.55 15
PY2022 $30,239.44 47
PY2023 $20,802.32 129
PY2024 $6,747.66 120
PY2025 $31,289.59 185

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $323,926.28 12
PY2024 Principal investigator $102,657.62 8
PY2023 Principal investigator $129,363.90 17
PY2022 Principal investigator $49,179.00 11
PY2021 Principal investigator $1,125.00 1
PY2020 Recipient $3,200.00 1
PY2020 Principal investigator $2,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $133,143.20 12/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185546951
Principal investigator 1 ABBVIE INC. $6,360.98 10/09/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202513995
Principal investigator 1 ABBVIE INC. $7,906.00 09/04/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202509724
Principal investigator 1 ABBVIE INC. $2,704.12 09/04/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202509726
Principal investigator 1 ABBVIE INC. $7,603.16 08/06/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202502729
Principal investigator 1 ABBVIE INC. $7,470.50 07/23/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202499324
Principal investigator 1 ABBVIE INC. $39,082.44 07/08/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202497234
Principal investigator 1 ABBVIE INC. $9,246.00 05/20/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202485493
Principal investigator 1 ABBVIE INC. $8,810.50 05/20/2025 Non-covered Recipient Entity
ALLISON CURTIS KINGSLEY
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202485495
Principal investigator 1 Janssen Research & Development, LLC $1,125.00 02/26/2025 Non-covered Recipient Entity
The Us Oncology Ntwrk
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd No dispute reported 06/30/2026 1175287536
Principal investigator 1 AstraZeneca Pharmaceuticals LP $98,126.98 01/29/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185546947
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,347.40 01/15/2025 Non-covered Recipient Entity
COMPREHENSIVE CANCER CENTERS OF NEVADA
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185546949